

## TABLE OF CONTENTS

<b>TITLE PAGE .....</b>	<b>i</b>
<b>APPROVAL PAGE .....</b>	<b>ii</b>
<b>AUTHENTICITY STATEMENT .....</b>	<b>iii</b>
<b>PREFACE.....</b>	<b>iv</b>
<b>TABLE OF CONTENTS .....</b>	<b>vi</b>
<b>LIST OF ABBREVIATION .....</b>	<b>viii</b>
<b>LIST OF FIGURES .....</b>	<b>ix</b>
<b>LIST OF TABLES .....</b>	<b>ix</b>
<b>ABSTRACT.....</b>	<b>x</b>
<b>ABSTRAK .....</b>	<b>xi</b>
<b>CHAPTER I .....</b>	<b>1</b>
A. Study Background .....	1
B. Problem Formulation.....	3
C. Objectives .....	4
D. Study Originality .....	6
E. Study Benefits .....	10
<b>CHAPTER II.....</b>	<b>11</b>
A. Literature Review .....	11
1. Ovarian Cancer .....	11
1.1 Clinical Manifestation .....	11
1.2 Risk Factors .....	13
1.2.1 Age.....	13
1.2.2 Parity .....	13
1.2.3 Body Mass Index (BMI) .....	14
1.3 Ovarian Cancer Classification.....	14
1.4 Tumor Grading .....	16
1.5 FIGO Staging.....	17
2. Tumor Necrosis Factor – alpha (TNF- $\alpha$ ) .....	18
3. Central Dogma of Molecular Biology .....	19
B. Theoretical Framework .....	21
C. Conceptual Framework .....	22
D. Hypothesis .....	22

<b>CHAPTER III .....</b>	<b>24</b>
A. Type and Study Design .....	24
B. Time and Study Setting .....	24
C. Study Variable .....	25
D. Operational Definition.....	26
E. Study Instruments .....	27
1. Study Population .....	27
2. Study Sample .....	27
3. Study Materials and Instruments .....	28
F. Data Collection Method .....	29
1. Sample Collection .....	29
1.1 Plasma Sample Collection .....	29
1.2 Total RNA Isolation .....	30
1.3 cDNA Synthesis .....	30
2. Quantitative Real-Time PCR .....	31
G. Data Analysis.....	32
H. Ethical Consideration .....	33
<b>CHAPTER IV.....</b>	<b>34</b>
A. Result.....	34
1. TNF- $\alpha$ mRNA Expression Based on Different Variables.....	36
B. Discussion.....	37
1. Baseline Characteristics .....	38
1.1 Age .....	38
1.2 Parity.....	39
1.3 BMI.....	40
2. TNF- $\alpha$ mRNA Expression Based on Tumor Characteristics.....	42
<b>CHAPTER V .....</b>	<b>46</b>
A. Conclusion.....	46
B. Suggestion .....	47
<b>REFERENCES.....</b>	<b>48</b>
<b>ATTACHMENTS .....</b>	<b>52</b>

## LIST OF ABBREVIATION

BMI	: Body Mass Index
CA-125	: Cancer-Antigen 125
CCL	: CC chemokine ligands
CRC	: Colorectal cancer
DD	: Death Domain
DNA	: Deoxyribonucleic acid
EOC	: Epithelial Ovarian Cancer
FIGO	: International Federation of Gynecology and Obstetrics
IFN- $\gamma$	: Interferon gamma
IKK	: I $\kappa$ B kinase
IL	: Interleukin
JNK	: c-Jun N-terminal kinases
MAPKs	: Mitogen-activated protein kinases
mRNA	: Messenger ribonucleic acid
NF- $\kappa$ B	: Nuclear factor kappa-light-chain-enhancer of activated B cells
OSE	: Ovarian surface epithelium
RNA	: Ribonucleic acid
ROS	: Reactive oxygen species
TNF- $\alpha$	: Tumor Necrosis Factor Alpha
TNFR	: Tumor Necrosis Factor Receptor
qRT-PCR	: Quantitative Real Time-Polymerase Chain Reaction

## LIST OF FIGURES

<b>Figure 1.</b> Theoretical Framework.....	21
<b>Figure 2.</b> Conceptual Framework.....	22

## LIST OF TABLES

<b>Table 1.</b> WHO Classifications of Ovarian Tumors 2014 .....	15
<b>Table 2.</b> FIGO Ovarian Cancer Staging .....	17
<b>Table 3.</b> Baseline characteristic .....	34
<b>Table 4.</b> Sample distribution based on tumor characteristics .....	35
<b>Table 5.</b> TNF- $\alpha$ mRNA expression in different variables .....	36
<b>Table 6.</b> TNF-alpha mRNA expressions based on histotype and tumor differentiation.....	42